Analyst Reco. Aquestive Therapeutics, Inc.

Equities

AQST

US03843E1047

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
2.75 ^USD	-2.14%		-4.51%	+36.14%

Jun. 06	Aquestive Therapeutics, Inc. Promotes Cassie Jung as Chief Operating Officer	CI
Jun. 03	Aquestive Therapeutics, Inc. Announces Executive Changes	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target	May. 10	MT
Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target	Apr. 11	MT
Raymond James Initiates Aquestive Therapeutics With Outperform Rating, $7 Price Target	Mar. 28	MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering	Mar. 20	MT
H.C. Wainwright Raises Price Target on Aquestive Therapeutics to $9 From $7, Maintains Buy Rating	Mar. 18	MT
JMP Securities Adjusts Price Target on Aquestive Therapeutics to $10 From $8, Maintains Market Outperform Rating	Mar. 15	MT
HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $7 From $6, Maintains Buy Rating	Mar. 11	MT
Wedbush Lifts Aquestive Therapeutics' PT to $9 From $4 After Model Adjustments, Keeps Outperform Rating	Mar. 07	MT
HC Wainwright Raises Price Target on Aquestive Therapeutics to $6 From $5, Maintains Buy Rating	Nov. 08	MT
Wedbush Lifts Aquestive Therapeutics' Price Target to $4 From $3 Due to Decreased Share Count, Keeps Outperform Rating	23-08-10	MT
Wedbush Trims Aquestive Therapeutics' PT to $3 From $4, Pushes US, EU Launch Estimates for Anaphylm/Anaphylaxis; Keeps Outperform Rating	23-07-03	MT
Wedbush Upgrades Aquestive Therapeutics to Outperform Rating From Neutral, Adjusts Price Target to $4 From $3	23-03-09	MT
Wedbush Downgrades Aquestive Therapeutics to Neutral From Outperform, Notes Limited Cash Runway; Trims Price Target to $3 From $4	23-01-31	MT
Alliance Global Partners Adjusts Price Target on Aquestive Therapeutics to $7 From $10, Maintains Buy Rating	22-11-04	MT
Oppenheimer Initiates Coverage on Aquestive Therapeutics With Outperform Rating, $8.50 Price Target	22-09-07	MT
HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $5 From $6, Reiterates Buy Rating	22-09-06	MT
BMO Capital Adjusts Aquestive Therapeutics' Price Target to $6 from $9, Maintains Outperform Rating	22-09-01	MT
Alliance Global Initiates Aquestive Therapeutics at Buy Rating With $10 Price Target	22-08-30	MT
Wedbush Adjusts Price Target on Aquestive Therapeutics to $4 From $8 on Potential Share Count Increase; Outperform Rating Kept	22-08-04	MT
HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $5 From $8, Reiterates Buy Rating	22-06-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Aquestive Therapeutics, Inc.

Equities

AQST

US03843E1047

Analyst Reco.

Filters